Inactive Instrument

Wuhan General Group (China), Inc. Stock price Other OTC

Equities

WUHN

US9825691051

Biotechnology & Medical Research

Sales 2011 128M Sales 2012 80.38M Capitalization 1.33M
Net income 2011 -3M Net income 2012 -10M EV / Sales 2011 0.55 x
Net Debt 2011 62.49M Net Debt 2012 100M EV / Sales 2012 1.26 x
P/E ratio 2011
-1.56 x
P/E ratio 2012
-0.12 x
Employees -
Yield 2011 *
-
Yield 2012
-
Free-Float 76.65%
More Fundamentals * Assessed data
Dynamic Chart
Institute of Biomedical Research Corp. Appoints Adrian J. Maizey to Advisory Board of M2Bio Sciences CI
Institute of Biomedical Research Corp. agreed to acquire Biomedical and Nutraceutical Assets of Wuhan General Group, Inc. (OTCPK : WUHN). CI
Wuhan General Group, Inc. reached an agreement to acquire a 40% stake in Tsime Pharmaceuticals Ltd from Bataung Likate and other shareholders. CI
Wuhan General Group, Inc. Announces Appointment of Michael Sachar as CEO of M2bio Sciences Food &Beverage CI
Wuhan General Group, Inc. announced that it expects to receive $0.45 million in funding from ThreeD Capital Inc. CI
Wuhan to Launch CBD Cosmetics and CBD Infused Coffee in South Africa CI
Wuhan General Group Appoints Hyder A. Khoja as Chief Scientific Officer CI
Wuhan General Group, Inc. Announces Strategic Reorganization to Capitalize Medical Marijuana and Psilocybin Mushroom Industries; Appoints Luka Marjanovic as Head of Product Development for the MJ MedTech Division in South Africa CI
Wuhan General Group, Inc. Expands Capacity to Produce Medicinal Marijuana and Mushrooms CI
Wuhan General Group, Inc. Provides Revenue Guidance for the Second Quarter, Third Quarter and Fourth Quarter of 2019 CI
Wuhan General Group, Inc. Announces Executive Appointments CI
Wuhan General Group, Inc. Announces Executive Changes CI
EPlay and Wuhan Announce Strategic Partnership to Create New Medical Cannabis App CI
Wuhan General Group, Inc. signed a non-binding Letter of Intent to acquire MJ MedTech Inc. CI
Wuhan General Group, Inc. Appoints Anna Leralta Morera as Chief Medical Officer CI
More news
Managers TitleAgeSince
Founder - 88-07-18
Director of Finance/CFO - 20-10-04
Chief Tech/Sci/R&D Officer - 21-08-31
Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer - 19-01-21
Founder - 88-07-18
More insiders
Wuhan General Group (China) Inc is a South Africa-based bioceutical company. The Company is focused on alternative plant-based cannabinoids and mental health therapeutic research. Through its subsidiary, Neur.ai, the Company is engaged in developing a portfolio of receptor agonists based on neurotransformational medicine for the treatment of mental illness. The Company develops and commercializes a range of cannabidiol (CBD) and mushrooms-based products under the Dr. AnnaRx, Medspresso, and Liviana brands. The brands span across a range of premium CBD- and mushroom-infused consumer goods, including bioceuticals, health and wellness, and precision foods and beverages. In addition, the Company's research and clinical trials with psilocybin are aimed at new therapies that seek to help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Its Liviana brand offers CBD-infused raw honey and CBD-infused extra virgin olive oils.
More about the company
  1. Stock
  2. Equities
  3. Stock Wuhan General Group (China), Inc.
  4. Stock Wuhan General Group (China), Inc. - Other OTC